Literature DB >> 22596184

What is the prevalence of resistant hypertension in the United States?

Dustin R Roberie1, William J Elliott.   

Abstract

PURPOSE OF REVIEW: Resistant hypertension, defined as blood pressure uncontrolled on three, or controlled with at least four, antihypertensive agents (including a diuretic), is associated with higher risk of secondary hypertension, cardiovascular and renal events, and increased healthcare expenditures. Until recently, however, the prevalence of resistant hypertension in the United States (US) was based on clinical trial registries or pharmacy databases. RECENT
FINDINGS: Recent analyses of National Health and Nutrition Examination Survey (NHANES) data, drawn from representative samples of the adult, noninstitutionalized, civilian population, have estimated the prevalence of resistant hypertension at 8.9  ±  0.6% of the US hypertensive population in 2003-2008. A time-sequence comparison of NHANES data from 1998 through 2008 suggests that, unlike hypertension, resistant hypertension is becoming more prevalent (e.g., 20.7% in 2005-2008), due to aging and increased obesity in the general population. Resistant hypertension was more frequent in people who were older, obese, male, African American or nonblack Hispanic.
SUMMARY: In coming years, even if the prevalence of hypertension remains stable, resistant hypertension is likely to increase, especially as the proportion of treated hypertension increases. Because of increased use of healthcare resources, resistant hypertensive patients should be identified early, and greater efforts made to control their blood pressures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22596184     DOI: 10.1097/HCO.0b013e328353ad6e

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  27 in total

Review 1.  Resistant Hypertension: An Update of Experimental and Clinical Findings.

Authors:  Anping Cai; David A Calhoun
Journal:  Hypertension       Date:  2017-05-15       Impact factor: 10.190

Review 2.  Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?

Authors:  Hamish Cg Prosser; Cynthia Gregory; Dagmara Hering; Graham S Hillis; Greg Perry; Johan Rosman; Carl Schultz; Mark Thomas; Gerald F Watts; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

3.  White-Coat Effect Is Uncommon in Patients With Refractory Hypertension.

Authors:  Mohammed Siddiqui; Eric K Judd; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2017-07-10       Impact factor: 10.190

Review 4.  Resistant hypertension--its identification and epidemiology.

Authors:  Pantelis A Sarafidis; Panagiotis Georgianos; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

Review 5.  Should All Patients with Resistant Hypertension Receive Spironolactone?

Authors:  Ján Rosa; Tomáš Zelinka; Ondřej Petrák; Branislav Štrauch; Robert Holaj; Jiří Widimský
Journal:  Curr Hypertens Rep       Date:  2016-11       Impact factor: 5.369

6.  Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.

Authors:  David A Calhoun; John N Booth; Suzanne Oparil; Marguerite R Irvin; Daichi Shimbo; Daniel T Lackland; George Howard; Monika M Safford; Paul Muntner
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

7.  Leptin Induces Hypertension Acting on Transient Receptor Potential Melastatin 7 Channel in the Carotid Body.

Authors:  Mi-Kyung Shin; Candela Caballero Eraso; Yun-Ping Mu; Chenjuan Gu; Bonnie H Y Yeung; Lenise J Kim; Xiao-Ru Liu; Zhi-Juan Wu; Omkar Paudel; Luis E Pichard; Machiko Shirahata; Wan-Yee Tang; James S K Sham; Vsevolod Y Polotsky
Journal:  Circ Res       Date:  2019-09-23       Impact factor: 17.367

Review 8.  Dysfunctional brain-bone marrow communication: a paradigm shift in the pathophysiology of hypertension.

Authors:  Monica M Santisteban; Jasenka Zubcevic; David M Baekey; Mohan K Raizada
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

Review 9.  Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure.

Authors:  Tanja Dudenbostel; Mohammed Siddiqui; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-04-18       Impact factor: 10.190

Review 10.  Resistant Hypertension: An Incurable Disease or Just a Challenge For Our Medical Skill?

Authors:  Marina Di Pilla; Rosa Maria Bruno; Stefano Taddei
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.